Board of Directors
CollaborationsCollaborations
At Nitec, we understand the importance of collaboration and partnership in the successful development of biopharmaceuticals. We seek to build long-term relationships with pharmaceutical partners, contract research organisations, contractors and other suppliers. We are always interested in hearing from companies interested in assisting us in the commercialization of our pipeline or from companies with products available for in-licensing.Contact Us
For further information please contact Jochen Mattis, Executive Vice President Marketing & Sales / Business Development on +49 (0) 621 438502 0 or +41 61 715 2047.
Existing partnerships:
- Merck KGaA – worldwide license to all intellectual property relating to Lodotra™
- Merck KGaA – commercialization of Lodotra™ in Germany and Austria
- Skyepharma AG – exclusive license to GeoClockTM technology (based on SkyePharma’s GeoMatrixTM technology) in combination with any glucocorticoid
- Jagotec AG (an affiliated company of SkyePharma) – manufacturing and supply of Lodotra™
- PAZ GmbH – worldwide license to all intellectual property relating to TruNoc (tarenflurbil)
24/10/2007
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
12/06/2008
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
